_1747381249 20250516074049000 Editor editor.jddt@gmail.com Universal Journal of Pharmaceutical Research Universal Journal of Pharmaceutical Research Univ J Pharm Res 2456-8058 2831-5235 05 15 2025 Adel Saleh Ali Sulaiman Al-Kasem Mohammed A Abbas Arij Lutf Abdulrhman Abdul Majid Fatima Mohammed Abdullah Al-Rohmi Ammar Qasem Hasan Al-Muntaser Khaled Abdulkarim Al-Moyed Hassan Abdulwahab Al-Shamahy Omar Ahmed Ismael Al-dossary Maha'a A. M. Al-Khorasani Rassam Abdo Saleh Alsubari Background and aims: Temporomandibular disorders (TMDs) are a collection of ailments that impact the temporomandibular joints and tissues, especially while chewing. The most prevalent type of TMD that causes discomfort and functional challenges is masticatory myofascial pain (MMP). Treatments for MPDS vary, with conservative and reversible therapies including behaviour adaptation, physical therapy, medicine, oral devices and patient education. The aim of this study is to test low-level laser therapy (LLLT) in reducing pain, increasing function, and improving range of motion and ability to perform daily activities in patients with MPS. Patients and Methods: This study was a prospective clinical trial designed twenty patients to assess the efficacy of LLLT as a treatment modality for MPS, including the incidence and severity of side effects. Results: The mean pain severity, measured using the Visual Analog Scale (VAS), significantly decreased from 7.5 (1.3 SD) in first Week and progressively reducing to 3.8 (1.0 SD) in six Week, indicating substantial pain reduction over the treatment period. The majority of patients showed significant improvement, with 95% of participants experiencing a reduction in pain severity (p<0.001). Conclusion: This study elucidated that LLLT may be regarded as an appropriate and non-invasive therapeutic approach for MPD. It was also effective, had promising outcomes, and can be utilized as a treatment for MP. Low-Level Laser Therapy (LLLT) is regarded as a preferred therapeutic option due to its short-term bio stimulatory, analgesic, anti-inflammatory, and regenerative benefits. LLLT shown minimal adverse effects and exhibited favorable patient acceptability.                   Peer Review History: Received 8 February 2025;   Reviewed 12 March 2025; Accepted 23 April; Available online 15 May 2025 05 15 2025 http://creativecommons.org/licenses/by-nc/4.0 10.22270/ujpr.v10i2.1314 https://ujpronline.com/index.php/journal/article/view/1314 https://ujpronline.com/index.php/journal/article/download/1314/1853 https://ujpronline.com/index.php/journal/article/download/1314/1853 https://ujpronline.com/index.php/journal/article/download/1314/1867 https://ujpronline.com/index.php/journal/article/download/1314/1876